CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
0 hedge funds and large institutions have $0 invested in CTI BioPharma Corp. (DE) Common Stock in 2023 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $474K → $0 (-$474K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$389K |
| 2 |
Legal & General Group
London,
United Kingdom
|
-$84.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS AM
Chicago,
Illinois
| – | -$389K | -92,700 | Closed |
|
|
2
Legal & General Group
London,
United Kingdom
| – | -$84.9K | -9,340 | Closed |
|
CTIC Hedge Fund Activity: Q3 2023 in Review
0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2023, worth a combined $0 — down 100% from $474K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CTIC and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was UBS AM, exiting entirely with an estimated $389K sold.
- 0 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2023, down from 2 in Q2 2023.
- Funds reported $0 of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2023 and 2 closed out, a net change of -2 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2023 was UBS AM, an estimated $389K sold.
Based on aggregated 13F filings for Q3 2023.